The  ||| S:0 E:4 ||| DT
history  ||| S:4 E:12 ||| NN
of  ||| S:12 E:15 ||| IN
sublingual  ||| S:15 E:26 ||| NNS
immunotherapy  ||| S:26 E:40 ||| VBP
The  ||| S:40 E:44 ||| DT
sublingual  ||| S:44 E:55 ||| JJ
route  ||| S:55 E:61 ||| NN
of  ||| S:61 E:64 ||| IN
administration  ||| S:64 E:79 ||| NN
of  ||| S:79 E:82 ||| IN
allergen  ||| S:82 E:91 ||| NNS
( ||| S:91 E:92 ||| -LRB-
SLIT ||| S:92 E:96 ||| NNP
)  ||| S:96 E:98 ||| -RRB-
has  ||| S:98 E:102 ||| VBZ
emerged  ||| S:102 E:110 ||| VBN
as  ||| S:110 E:113 ||| IN
an  ||| S:113 E:116 ||| DT
effective  ||| S:116 E:126 ||| JJ
treatment ||| S:126 E:135 ||| NN
.  ||| S:135 E:137 ||| .
Other  ||| S:137 E:143 ||| JJ
non-injective  ||| S:143 E:157 ||| JJ
route  ||| S:157 E:163 ||| NN
of  ||| S:163 E:166 ||| IN
administration  ||| S:166 E:181 ||| NN
of  ||| S:181 E:184 ||| IN
vaccines  ||| S:184 E:193 ||| NNS
failed  ||| S:193 E:200 ||| VBD
their  ||| S:200 E:206 ||| PRP$
goals ||| S:206 E:211 ||| NNS
;  ||| S:211 E:213 ||| :
oral  ||| S:213 E:218 ||| JJ
immunotherapy  ||| S:218 E:232 ||| NNS
( ||| S:232 E:233 ||| -LRB-
OIT ||| S:233 E:236 ||| NNP
) ||| S:236 E:237 ||| -RRB-
,  ||| S:237 E:239 ||| ,
local  ||| S:239 E:245 ||| JJ
nasal  ||| S:245 E:251 ||| JJ
immunotherapy  ||| S:251 E:265 ||| NNS
( ||| S:265 E:266 ||| -LRB-
LNIT ||| S:266 E:270 ||| NNP
) ||| S:270 E:271 ||| -RRB-
,  ||| S:271 E:273 ||| ,
local  ||| S:273 E:279 ||| JJ
bronchial  ||| S:279 E:289 ||| JJ
immunotherapy  ||| S:289 E:303 ||| NNS
( ||| S:303 E:304 ||| -LRB-
LBIT ||| S:304 E:308 ||| NNP
)  ||| S:308 E:310 ||| -RRB-
were  ||| S:310 E:315 ||| VBD
reported  ||| S:315 E:324 ||| VBN
as  ||| S:324 E:327 ||| IN
too  ||| S:327 E:331 ||| RB
expensive  ||| S:331 E:341 ||| JJ
or  ||| S:341 E:344 ||| CC
unsafe  ||| S:344 E:351 ||| JJ
or  ||| S:351 E:354 ||| CC
ineffective ||| S:354 E:365 ||| JJ
.  ||| S:365 E:367 ||| .
Oral  ||| S:367 E:372 ||| JJ
regimens  ||| S:372 E:381 ||| NN
were  ||| S:381 E:386 ||| VBD
used  ||| S:386 E:391 ||| VBN
in  ||| S:391 E:394 ||| IN
the  ||| S:394 E:398 ||| DT
first  ||| S:398 E:404 ||| JJ
half  ||| S:404 E:409 ||| NN
of  ||| S:409 E:412 ||| IN
the  ||| S:412 E:416 ||| DT
20th  ||| S:416 E:421 ||| JJ
century  ||| S:421 E:429 ||| NN
but  ||| S:429 E:433 ||| CC
then  ||| S:433 E:438 ||| RB
they  ||| S:438 E:443 ||| PRP
lost  ||| S:443 E:448 ||| VBD
ground  ||| S:448 E:455 ||| NN
to  ||| S:455 E:458 ||| TO
injection  ||| S:458 E:468 ||| VB
immunotherapy ||| S:468 E:481 ||| NNS
.  ||| S:481 E:483 ||| .
SLIT  ||| S:483 E:488 ||| NNP
is  ||| S:488 E:491 ||| VBZ
suitable  ||| S:491 E:500 ||| VBN
for  ||| S:500 E:504 ||| IN
home  ||| S:504 E:509 ||| NN
treatment  ||| S:509 E:519 ||| NN
and  ||| S:519 E:523 ||| CC
it  ||| S:523 E:526 ||| PRP
has  ||| S:526 E:530 ||| VBZ
not  ||| S:530 E:534 ||| RB
to  ||| S:534 E:537 ||| TO
be  ||| S:537 E:540 ||| VB
regarded  ||| S:540 E:549 ||| VBN
not  ||| S:549 E:553 ||| RB
only  ||| S:553 E:558 ||| RB
as  ||| S:558 E:561 ||| IN
a  ||| S:561 E:563 ||| DT
substitute  ||| S:563 E:574 ||| NN
of  ||| S:574 E:577 ||| IN
subcutaneous  ||| S:577 E:590 ||| JJ
immunotherapy  ||| S:590 E:604 ||| NNS
( ||| S:604 E:605 ||| -LRB-
SCIT ||| S:605 E:609 ||| NNP
) ||| S:609 E:610 ||| -RRB-
,  ||| S:610 E:612 ||| ,
but  ||| S:612 E:616 ||| CC
also  ||| S:616 E:621 ||| RB
as  ||| S:621 E:624 ||| IN
a  ||| S:624 E:626 ||| DT
complementary  ||| S:626 E:640 ||| JJ
or  ||| S:640 E:643 ||| CC
additional  ||| S:643 E:654 ||| JJ
therapeutic  ||| S:654 E:666 ||| JJ
tool  ||| S:666 E:671 ||| NN
in  ||| S:671 E:674 ||| IN
conventional  ||| S:674 E:687 ||| JJ
medical  ||| S:687 E:695 ||| JJ
practice ||| S:695 E:703 ||| NN
.  ||| S:703 E:705 ||| .
Currently ||| S:705 E:714 ||| RB
,  ||| S:714 E:716 ||| ,
the  ||| S:716 E:720 ||| DT
balance  ||| S:720 E:728 ||| NN
sheet  ||| S:728 E:734 ||| NN
for  ||| S:734 E:738 ||| IN
SLIT  ||| S:738 E:743 ||| NNP
is  ||| S:743 E:746 ||| VBZ
improving ||| S:746 E:755 ||| VBG
:  ||| S:755 E:757 ||| :
with  ||| S:757 E:762 ||| IN
the  ||| S:762 E:766 ||| DT
steadily  ||| S:766 E:775 ||| RB
increasing  ||| S:775 E:786 ||| VBG
number  ||| S:786 E:793 ||| NN
of  ||| S:793 E:796 ||| IN
patients  ||| S:796 E:805 ||| NNS
with  ||| S:805 E:810 ||| IN
IgE  ||| S:810 E:814 ||| JJ
mediated  ||| S:814 E:823 ||| JJ
disorders ||| S:823 E:832 ||| NNS
,  ||| S:832 E:834 ||| ,
looking  ||| S:834 E:842 ||| VBG
for  ||| S:842 E:846 ||| IN
a  ||| S:846 E:848 ||| DT
cheap ||| S:848 E:853 ||| JJ
,  ||| S:853 E:855 ||| ,
safe  ||| S:855 E:860 ||| JJ
and  ||| S:860 E:864 ||| CC
effective  ||| S:864 E:874 ||| JJ
therapy  ||| S:874 E:882 ||| NN
becomes  ||| S:882 E:890 ||| VBZ
a  ||| S:890 E:892 ||| DT
priority ||| S:892 E:900 ||| NN
.  ||| S:900 E:902 ||| .
